<h4>Purpose</h4>Reliable assessment of androgen receptor (AR) status in triple-negative breast cancer (TNBC) is critical for targeted therapy but remains challenging due to biopsy limitations from intratumoral heterogeneity. This evidence concerns the gene AR and triple-negative breast carcinoma.